Targets › KEAP1
4 programs from 4 companies in 4 trials: 3 Phase 2, 1 Phase 3; Neurology, Ophthalmology, Oncology; next expected readout Apr 2027.
Substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin ligase complex that regulates the response to oxidative stress by targeting NFE2L2/NRF2 for ubiquitination. KEAP1 acts as a key sensor of oxidative and electrophilic stress: in normal conditions, the BCR(KEAP1) complex mediates ubiquitination and degradation of NFE2L2/NRF2, a transcription factor regulating expression of many cytoprotective genes. (UniProt, Q14145)
Open in Phaseline: the race on KEAP1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University Hospital, Montpellier | Dimethyl Fumarate Kelch-like ECH-associated protein 1 inhibitor | KEAP1 | Phase 3 | Relapsing-Remitting Multiple Sclerosis (RRMS) | Jun 2031 |
| Assistance Publique - Hôpitaux de Paris | Dimethyl Fumarate Kelch-like ECH-associated protein 1 inhibitor | KEAP1 | Phase 2 | Age-related Macular Degeneration (AMD) | Apr 2027 |
| NYU Langone Health | DRP-104 Glutamine antagonist | NFE2L2, KEAP1 | Phase 2 | Non Small Cell Lung Cancer | Oct 2027 |
| Medical University of Lodz | dimethyl fumarate Kelch-like ECH-associated protein 1 inhibitor | KEAP1 | Phase 2 | MCI | Dec 2027 |
Age-related Macular Degeneration (AMD) (1) MCI (1) Non Small Cell Lung Cancer (1) Relapsing-Remitting Multiple Sclerosis (RRMS) (1)
small molecule (3), mixed (1)
Assistance Publique - Hôpitaux de Paris (1) Medical University of Lodz (1) NYU Langone Health (1) University Hospital, Montpellier (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.